Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-16T19:05:58.778Z Has data issue: false hasContentIssue false
  • English
  • Français

Sleep quality in schizophrenia and the effects of atypical antipsychotic medication

Published online by Cambridge University Press:  24 June 2014

P. M. Judith Haffmans ,
Hans J. Oolders ,
Erik Hoencamp  and
Andreas Schreiner
P. M. Judith Haffmans*
Affiliation:
Department of Research, Parnassia, Den Haag, the Netherlands
Hans J. Oolders
Affiliation:
Department of Research, Parnassia, Den Haag, the Netherlands
Erik Hoencamp
Affiliation:
Department of Research, Parnassia, Den Haag, the Netherlands
Andreas Schreiner
Affiliation:
Department of Medical and Scientific Affairs, Janssen-Cilag, Neuss, Germany
*
P. M. J. Haffmans, Department of Research, Parnassia Psycho-Medical Center, Monsterseweg 83, NL-2558 RJ, Den Haag, the Netherlands. Tel: +31 70 391 6582; Fax: +31 70 391 6146; E-mail: j.haffmans@parnassia.nl
Get access Rights & Permissions [Opens in a new window]

Abstract

Background:

Sleep disorders are widespread among patients with schizophrenia and contribute to adverse clinical outcomes. Antipsychotic drugs exert varying effects on sleep, and the effects of atypical agents may differ from those of conventional neuroleptics.

Objective:

To review the literature on the effects of atypical medication on subjective and objective sleep quality in patients with schizophrenia.

Methods:

A non-systematic literature review of Medline was performed in August 2003 searching the period from January 1985 to August 2003 for studies of the effects of atypical antipsychotics on sleep.

Results:

We found published studies of clozapine, olanzapine, and risperidone, but none on quetiapine or ziprasidone. Studies with clozapine showed that it increased total sleep time, sleep efficiency, stage-2 non-rapid eye movement sleep and rapid eye movement (REM) sleep density, and decreased stage-4 sleep, slow wave sleep (SWS) and stage-1 sleep. Single-dose studies with olanzapine have shown that it increases SWS, sleep continuity, total sleeping time, subjective sleep quality, and delta sleep. Long-term studies with risperidone have shown improvements in total sleep, sleep efficiency, sleep continuity, SWS, and stage-2 sleep, and reductions in sleep latency, number of awakenings, and proportion of time awake. These benefits were paralleled by improvements in subjective sleep assessment and psychopathology, and psychosocial functioning.

Conclusions:

The evidence presented in this review suggests that atypical antipsychotics exert favorable effects on sleep profile compared with conventional agents, including improvement of subjective sleep quality and modification of specific sleep stages known to be associated with better clinical outcome.

Keywords

atypical antipsychoticsclozapineolanzapinerisperidoneschizophreniasleep disorders
Type
Original Article
Information
Acta Neuropsychiatrica , Volume 16 , Issue 6 , December 2004 , pp. 281 - 289
Copyright
Copyright © 2004 Blackwell Munksgaard

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Dursun, SM, Patel, JKM, Burke, JGet al. Effects of typical antipsychotic drugs and risperidone on the quality of sleep in patients with schizophrenia: a pilot study. J Psychiatry Neurosci 1999;24: 333–337. Google ScholarPubMed
Haffmans, PMJ, Hoencamp, E, Knegtering, HJet al. Sleep disturbance in schizophrenia. Br J Psychiatry 1994;65: 697–698. CrossRefGoogle Scholar
van Kammen, DP, van Kammen, WB, Peters, JLet al. CSF MHPG, sleep and psychosis in schizophrenia. Clin Neuropharmacol 1986;9: 575–577. Google Scholar
Keshavan, MS, Reynolds, CF, Kupfer, DJ. Electro-encephalographic sleep in schizophrenia: a critical review. Compr Psychiatry 1990;30: 34–47. CrossRefGoogle Scholar
Dement, W. Dream recall and eye movements during sleep in schizophrenics and normals. J Nerv Ment Dis 1955;122: 263–269. CrossRefGoogle ScholarPubMed
Rechtschaffen, A, Schulsinger, F, Mednick, S. Schizophrenia and physiological indices of dreaming. Arch Gen Psychiatry 1964;10: 89–93. CrossRefGoogle ScholarPubMed
Tandon, R, Shipley, JE, Eiser, ASet al. Association between abnormal REM sleep and negative symptoms in schizophrenia. Psychiatry Res 1989;27: 359–361. CrossRefGoogle ScholarPubMed
Taylor, SF, Tandon, R, Shipley, JEet al. Sleep onset REM periods in schizophrenic patients. Biol Psychiatry 1991;30: 205–209. CrossRefGoogle ScholarPubMed
Keshavan, MS, Reynolds, CF III, Miewald, Jet al. Slow-wave sleep deficits and outcome in schizophrenia and schizoaffective disorder. Acta Psychiatr Scand 1995;91: 289–292. CrossRefGoogle Scholar
Kato, M, Kajimura, N, Okuma, Tet al. Association between delta waves during sleep and negative symptoms in schizophrenia. Neuropsychobiology 1999;39: 165–172. CrossRefGoogle ScholarPubMed
Kaplan, J, Dawson, S, Vaughan, Tet al. Effect of prolonged chlorpromazine administration on the sleep of chronic schizophrenics. Arch Gen Psychiatry 1974;31: 62–66. CrossRefGoogle ScholarPubMed
Gillin, JC, Van Kammen, DP, Post, Ret al. Effects of prolonged administration of pimozide on sleep-EEG patterns in psychiatric patients. Commun Psychopharmacol 1977;1: 225–232. Google ScholarPubMed
Keshavan, M, Reynolds, C, Brar, Jet al. Sleep EEG changes in schizophrenia during haloperidol treatment. Biol Psychiatry 1989;25: 181A. CrossRefGoogle Scholar
Taylor, SF, Tandon, R, Shipley, JEet al. Effect of neuroleptic treatment on polysomnographic measures in schizophrenia. Biol Psychiatry 1991;30: 904–912. CrossRefGoogle ScholarPubMed
Tandon, R, Elser, A, Taylor, Set al. Effects of clozapine, risperidone and olanzapine on polysomnographic measures in schizophrenia. Schizophr Res 2000;41: 156. CrossRefGoogle Scholar
Blum, A, Girke, W. Marked increase in REM sleep produced by a new antipsychotic compound. Clin Electroencephalogr 1973;4: 80–84.CrossRefGoogle Scholar
Ruther, E, Davis, L, Papousek, Met al. Pharmakologische Beeinflussung zentraler serotonerger Mechanismen am Menschen und Auswirkung auf den Schlaf. Drug Res 1976;26: 1071–1073.Google Scholar
Hinze-Selch, D, Mullington, J, Orth, Aet al. Effects of clozapine on sleep: a longitudinal study. Biol Psychiatry 1997;42: 260–266. CrossRefGoogle ScholarPubMed
Lee, Jh, Woo, JI, Meltzer, HY. Effects of clozapine on sleep measures and sleep-associated changes in growth hormone and cortisol in patients with schizophrenia. Psychiatr Res 2001;103: 157–166. CrossRefGoogle ScholarPubMed
Wetter, TC, Lauer, CJ, Gillich, Get al. The electroencephalographic sleep pattern in schizophrenic patients treated with clozapine or classical antipsychotic drugs. J Psychiatr Res 1996;30: 411–419. CrossRefGoogle ScholarPubMed
Sharpley, AL, Vassallo, CM, Cowen, PJ. Olanzapine increases slow-wave sleep: evidence for blockade of central 5-HT2c receptors in vivo. Biol Psychiatry 2000;47: 468–470. CrossRefGoogle Scholar
Sharpley, AL, Vassallo, CM, Pooley, EC, Harrison, PJ, Cowen, PJ. Allelic variation in the 5-TH2c receptor (HT2RC) and the increase in slow wave sleep produced by olanzapine. Psychpharmacology 2001;153: 271–272. CrossRefGoogle Scholar
Lindberg, N, Virkkunen, M, Tani, Pet al. Effect of a single-dose of olanzapine on sleep in healthy females and males. Int Clin Psychopharmacol 2002;17: 177–184. CrossRefGoogle ScholarPubMed
Salin-Pascual, RJ, Herrera-Estrella, M, Galicia-Polo, Let al. Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biol Psychiatry 1999;46: 141–143. CrossRefGoogle ScholarPubMed
de Buck, R, Hoffman, G, De Smet, Set al. Risperidone in young chronic schizophrenic patients: a polysomnographic study. Biol Psychiatry 1991;29 (11S):419S. Google Scholar
Williams, R. Optimal dosing with risperidone: update recommendations. J Clin Psychiatry 2001; 62: 282–289. CrossRefGoogle Scholar
Royuela-Rioo, A, Macias, JA, Aguado, JA. Effect of chronic use of risperidone on sleep quality. Int J Neuropsychopharmacol 1999;2: 102–103. Google Scholar
Royuela, A, Macias, JA. Effects of risperidone and other antipsychotic agents on sleep quality. Eur Neuropsychopharmacol 1997;7: S210. CrossRefGoogle Scholar
Crosthwaite, CG, Reveley, MA. Improved sleep with risperidone compared with conventional antipsychotic drugs in older patients with psychosis. Schizophr Res 2000;41: 202. CrossRefGoogle Scholar
Spitzer, RL, Gibbon, M, Endicott, J. The global assessment scale: a procedure for measuring overall severity of psychiatric disturbances. Arch General Psychiatry 1976;33: 766–771. Google Scholar
Haffmans, PMJ, Oolders, H, Hoencamp, Eet al. The effect of risperidone versus haloperidol on sleep patterns of schizophrenic patients: results of a double blind randomised pilot trial. Eur Neuropsychopharmacol 2001;11: S260. CrossRefGoogle Scholar
Yamashita, H, Morinobu, S, Yamawaki, S, Horiguchi, J, Nagao, M. Effect of risperidone on sleep in schizophrenia: a comparison with haloperidol. Psychiatry Res 2002;109: 137–142. CrossRefGoogle ScholarPubMed
Seeman, P, Chau-Wong, M, Wong, K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976;261: 717–719. CrossRefGoogle ScholarPubMed
Gottesmann, C. The neurochemistry of waking and sleeping mental activity: the disinhibition-dopamine hypothesis. Psychiatry Clin Neurosci 2002;56: 345–354. CrossRefGoogle ScholarPubMed
Leysen, JE, Janssen, PMF, Heylen, Let al. Receptor interactions of new antipsychotics: Relation to pharmacodynamic and clinical effects. Int J Psychiatry Clin Pract 1998;2: S3–S17. Google Scholar
Jouvet, M. Biogenic amines and the states of sleep. Science 1969;163: 32–41. CrossRefGoogle ScholarPubMed
Koella, WP. Serotonin and sleep. In: Koella, WP, Ruther, E, Schuiz, H, eds. Sleep, 1984. Proceedings of the Seventh European Congress on Sleep Research. Stuttgart: Gustav Fischer Verlag, 1985: 6–10. Google Scholar
Sharpley, AL, Elliot, JM, Attenburrow, M-Jet al. Slow wave sleep in humans; role of 5-HT1 and 5-HT2 receptors. Neuropharmacology 1994;33: 467–471. CrossRefGoogle Scholar
Sharpley, AL, Cowen, PJ. Effect of pharmacologic treatment on the sleep of depressed patients. Biol Psychiatry 1995;37: 85–98. CrossRefGoogle ScholarPubMed
Janssen, P, Niemegeers, C, Awouters, Fet al. Pharmacology of risperidone (R64766), a new neuroleptic with serotonin S2 and dopamine D2 antagonistic properties. J Pharmacol Exp Ther 1988; 244: 685–693. Google ScholarPubMed
Leysen, J, Janssen, P, Gommeren, Wet al. In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel neuroleptics risperidone and ocaperidone. Mol Pharmacol 1992;41: 494–508. Google ScholarPubMed
Rues, VI. Olanzapine: a novel atypical neuroleptic agent. Lancet 1997;349: 1264–1265. CrossRefGoogle Scholar
Mason, SL, Reynolds, GP. Clozapine has sub-micromolar affinity for 5-HT1A receptors in human brain tissue. Eur J Pharmacol 1992;221: 397–398. CrossRefGoogle ScholarPubMed
Driver, HS, Flanigan, MJ, Bentley, AJet al. The influence of ipsaspirone, a 5-HT1A agonist, on sleep patterns of healthy subjects. Psychopharmacology 1995;117: 186–192. CrossRefGoogle Scholar
Schwalen, S. Risperidone (Risperdal®) effects on sleep-wake cycle disturbances in dementia. Int Psychogeriatr 2001;13 (Suppl. 2): P–261. Google Scholar
Nofzinger, EA, Van Kammen, DP, Gilbertson, MWet al. Electroencephalographic sleep in clinically stable schizophrenic patients: two-week versus six-week neuroleptic-free. Biol Psychiatry 1993;33: 829–835. CrossRefGoogle Scholar
Neylan, TC, Van Kammen, DP, Kelley, MEet al. Sleep in schizophrenic patients on and off haloperidol therapy: clinically stable versus relapsed patients. Arch Gen Psychiatry 1992;49: 643–649. CrossRefGoogle Scholar
Campbell, A, Baldessarini, RJ. Prolonged pharmacologic activity of neuroleptics. Arch Gen Psychiatry 1985;42: 637. CrossRefGoogle ScholarPubMed